Background. Patients with cirrhosis are at high risk of Clostridium difficile infection (CDI). Rifaximin is commonly used in cirrhotic patients as prophylaxis for hepatic encephalopathy (HE). Several studies have demonstrated the efficacy of rifaximin in the treatment of CDI; however, resistance to rifaximin has also been reported. Few studies have assessed the risk of developing CDI in cirrhotic patients receiving rifaximin. Our objective was to assess the incidence and characteristics of CDI in patients with cirrhosis, especially in those who received rifaximin.
Clostridium difficile infection (CDI) is the leading cause of hospital-acquired diarrhea in developed countries [1] [2] [3] [4] . Patients with cirrhosis are at a particularly high risk of CDI, and outcome in this group has been shown to be poor [5] [6] [7] [8] . Few studies have assessed the incidence of CDI in cirrhotic patients; the CDI rate in cirrhotics has been reported to be between 0.2% and 11% [9] [10] [11] , with most of the studies reporting higher rates of CDI in cirrhotic and liver transplant patients than in the general population [5] [6] [7] 12] .
Hepatic encephalopathy (HE) is one of the major complications of liver cirrhosis [13] . Rifaximin, a rifamycin derivative, is commonly used as prophylaxis for recurrent HE in patients with cirrhosis. Rifaximin (550 mg twice daily) has shown to reduce the recurrence of overt HE and HE-related hospitalizations [14] . Furthermore, several studies have demonstrated the efficacy of rifaximin in the treatment of CDI that does not respond to conventional treatment [15] and as an adjunctive treatment to decrease recurrent CDI [16, 17] .
However, resistance to rifaximin by C. difficile strains has also been reported [18] [19] [20] . The few studies that have assessed the risk of developing CDI in cirrhotic patients receiving rifaximin show a reduced risk of or total protection against CDI [10] .
Our objective was to assess the incidence and characteristics of CDI in cirrhotic patients, especially those who received rifaximin for the treatment/prevention of HE.
MATERIALS AND METHODS

Setting
Our institution is a large teaching hospital with 1550 beds. The clinical microbiology laboratory receives samples from patients hospitalized at our center and from all the outpatient institutions in our catchment area.
testing for toxigenic C. difficile was performed on all diarrheic stool samples.
Laboratory Procedure
Diagnostic Sample Processing
Stool samples received in the laboratory were processed for diagnosis of CDI regardless of clinical suspicion. Stool samples transported in formaldehyde and formed samples were excluded. Rectal exudates and colon biopsy specimens were accepted in the case of patients with paralytic ileus or megacolon.
Samples sent with clinical suspicion of CDI were processed using the toxigenic C. difficile rapid detection test and direct cytotoxicity test. The rapid detection test consisted of a diagnostic algorithm based on immunochromatographic antigen detection (C Diff Quik-Chek Complete assay, TechLab, Blacksburg, Virginia) and on a real-time polymerase chain reaction (PCR) of the B toxin gene (Xpert C. difficile Assay, GeneXpert, Cepheid, Sunnyvale, California). Direct cytotoxicity testing was performed using the MRC-5 cell line according to a previously described procedure [21] .
Additionally, all samples underwent toxigenic culture in selective C. difficile agar (bioMeriéux). Identification of colonies suspected of being toxigenic C. difficile was confirmed using immunochromatography (C Diff Quik-Chek Complete assay, TechLab, Blacksburg, Virginia) and the MRC-5 cell line cytotoxicity test.
A positive result for toxigenic C. difficile was regarded as any sample with a positive result by any of the reference techniques (toxigenic culture or direct cytotoxicity in stool).
Antimicrobial Susceptibility Testing
Susceptibility to rifaximin was tested using the agar dilution method according to the procedures of the Clinical and Laboratory Standards Institute (CLSI) [22] . Rifaximin was obtained from Sigma Chemical Company (St Louis, Missouri). Quality control strains included C. difficile ATCC 700057, Bacteroides fragilis ATCC 25285, and Bacteroides thetaiotamicron ATCC 29741 [23] . The range of rifaximin concentrations tested was 0.0009-256 g/L. The minimum inhibitory concentrations (MICs) were recorded for each isolate after 48 hours' incubation following CLSI recommendations [22] . As no rifaximin CLSI clinical breakpoints are available for C. difficile, isolates that exhibited MICs >32 mg/L for rifaximin were considered resistant based on the existing literature [19, 20, [24] [25] [26] [27] [28] .
Ribotyping
All isolates were characterized using PCR ribotyping [29] . Phylogenetic analysis of ribotyping profiles was conducted using the unweighted pair group method with arithmetic mean and Dice coefficients (Bionumerics 5.0). Ribotypes were named using the international designation [29] . When the correspondence with international ribotypes was unknown, the letter R followed by a number was used.
Definitions
A CDI episode was defined as the presence of a positive result for toxigenic C. difficile testing and the presence of diarrhea (≥3 unformed stools in 24 hours) or colonoscopic findings demonstrating pseudomembranous colitis.
Severity of CDI was defined according to the guidelines of the Society of Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) [30] .
An episode was considered a recurrence if after recovery from a previous episode (at least 3 days without diarrhea and clinical improvement), symptoms returned and a stool sample separated from the former by between 15 and 60 days proved to be positive. Episodes occurring >60 days after the previous one were not considered recurrences but new episodes.
Death was considered CDI related when it was not attributable to other unrelated causes occurring within 10 days of the CDI diagnosis and/or due to well-known complications of CDI.
Clinical Data
The data collected included age, sex, and hospital department or outpatient clinic at the time of the episode of diarrhea. Data regarding the underlying condition were recorded using the McCabe and Jackson score for prognosis of underlying diseases; comorbidity was graded according to the Charlson index [31, 32] .
The clinical data recorded for the episode of diarrhea were days of diarrhea, presence of abdominal pain, abdominal distension, fever, hypotension, toxic megacolon, pseudomembranous colitis, severity of the CDI episode, and antibiotic treatment for the CDI episode. Outcomes (treatment failure, recurrence, mortality, and CDI-related mortality) were also recorded.
Data Analysis
Data were analyzed using PASW Statistics for Windows, version 18.0 (SPSS Inc, Chicago, Illinois). Qualitative variables appear with their frequency distribution. Quantitative variables are expressed as the median and interquartile range (IQR). Groups were compared using the Fisher exact test for categorical variables and the Mann-Whitney test or t test for continuous variables. A multivariate logistic regression model was used to assess risk factors for CDI. The odds ratio (OR) and 95% confidence interval (CI) were calculated. A P value < .05 was considered significant.
Ethical Issues
This study was approved by the Ethics Committee of Hospital General Universitario Gregorio Marañón.
RESULTS
During the study period, the microbiology laboratory received samples from 20 036 patients, of which 2440 (12.2%) were positive for toxigenic C. difficile. The study population comprised 388 cirrhotic patients, of whom 127 had had at least 1 episode of diarrhea in which a sample was sent to the microbiology laboratory. CDI was confirmed in 46 patients (11.9%). Fortyfour strains were available for susceptibility and molecular analysis.
The demographic and clinical characteristics of all cirrhotic patients with CDI due to rifaximin-resistant and -susceptible strains are shown in Table 1 . The majority of patients were male (69.6%), median age was 51 years, and the most frequent cause of cirrhosis was viral hepatitis (54.3% and 4.4% for hepatitis C virus and hepatitis B virus, respectively) followed by alcohol abuse (39.1%). The median Model for End-Stage Liver Disease (MELD) score was 12, and the median Child-Pugh score was 8.0. Among cirrhosis complications, 45.7% of the patients presented HE, and most patients had HE stage 2 (61.9%) or stage 1 (28.6%).
As for risk factors for CDI, approximately 91% of patients had received antibiotics and 78.3% had received proton pump inhibitors. Many patients had been mechanically ventilated (19.6%) and had undergone surgery (17.4%) in the month prior to the CDI episode. Fourteen patients (30.4%) were receiving rifaximin as prophylaxis against HE. The distribution of time to breakthrough CDI in patients receiving rifaximin is shown in Figure 1 . The median number of days of rifaximin therapy received prior to CDI was 69.0 (IQR, 23.0-391.3 days).
Most of the CDI episodes were mild to moderate (84.8%); CDI was considered severe in 10.9% of the patients and severe to complicated in 4.3%. We did not observe any statistically significant differences regarding CDI severity between patients who had received rifaximin and those without rifaximin treatment (mild to moderate: 92.9% vs 81.3%, P = .413; severe: 0.0% vs 15.6%, P = .303; severe to complicated: 7.1% vs 3.1%, P = .521). The CDI recurrence rate was 14%, and the overall mortality was 8.7%. Mortality was considered to be CDI related in 1 patient (2.2%).
The main ribotypes found were 001 (30.4%), followed by 014 (19.6%) and 078/126 (6.5%). The distribution of the ribotypes is shown in Figure 2 . Overall, the C. difficile resistance rate to rifaximin was 34.1% in cirrhotic patients with CDI and 84.6% in cirrhotic patients with CDI who had previously received rifaximin.
The comparison between cirrhotic patients with CDI due to rifaximin-resistant strains and rifaximin-susceptible strains revealed no significant differences in Charlson comorbidity index, etiology of cirrhosis, or severity of liver disease (eg, MELD score, Child-Pugh score). No significant differences were found for most of the laboratory parameters, severity of diarrhea, or days of diarrhea. No differences were observed for length of stay, intensive care unit admission, recurrence, or mortality.
However, patients with CDI due to rifaximin-resistant strains were significantly more frequently female (53.3% vs 20.7%; P = .042), more frequently had portal hypertension (86.7% vs 55.2%; P = .048), more frequently had HE (73.3% vs 31.0%; P = .011), and had more frequently received rifaximin for HE (80.0% vs 6.9%; P < .001) and rifamycins (rifaximin and/or rifampicin) (86.7% vs 6.9%; P < .001). Rifaximin-resistant C. difficile strains were more frequently ribotype 001 strains (86.7% vs 4.0%; P < .001) than those that were rifaximin-susceptible.
We performed a multivariable logistic regression analysis to identify the risk factors for having a rifaximin-resistant C. difficile strain, including all variables with P < .05. After backward elimination, prior therapy with rifamycins (OR, 42.1 [95% CI, 2.1-828.0]; P = .014) and having a ribotype 001 strain (OR, 42.1 [95% CI, 2.1-828.0]; P = .014) were significant risk factors for having a rifaximin-resistant C. difficile strain.
DISCUSSION
A significant proportion of CDI cases in cirrhotic patients in our institution were in patients receiving rifaximin for HE. Most causative C. difficile strains were found to be rifaximin resistant and belong mainly to ribotype 001.
Most studies assessing rifaximin therapy in HE show that the risk for CDI is low or nonexistent. Neff et al reviewed 211 patients who had received rifaximin for HE (mean of 250 days of rifaximin and mean dose of 1055 mg/day); of these, 8.5% developed diarrhea, and no cases were caused by toxigenic C. difficile [33] . In a retrospective UK multicenter study by Patel et al, no cases of CDI were reported in 170 patients receiving rifaximin for HE with a mean of 79 days of treatment [34] .
Moreover, in a systematic review and meta-analysis on the use of rifaximin for HE [35] in which the authors gathered data on adverse events from 13 randomized trials, there was no increased risk of resistance to rifaximin or other antibiotics or CDI in patients receiving rifaximin for HE.
A limited number of cases of CDI have been reported in patients receiving long-term rifaximin therapy [10, 14, 36] . Ours is the first study to encounter such a high number of CDI cases in patients receiving rifaximin. We found that almost onethird of CDI cases in cirrhotic patients occurred in patients receiving rifaximin. It is important to note that breakthrough CDI in patients receiving rifaximin can occur as soon as 9 days after starting treatment; therefore, caution is warranted both in short-term and in long-term treatment.
Most in vitro studies of rifaximin showed good antibacterial activity against C. difficile and only rare development of resistant clones [19, 37, 38] . However, a study performed at our institution in patients from the whole institution and from 13 outpatient clinics revealed a resistance rate of 32.2% [39] . Rifaximin resistance rates as high as 29% were recently reported for C. difficile in China [18] .
We found no significant differences between episodes caused by rifaximin-resistant strains and rifaximin-susceptible strains with respect to severity of diarrhea, recurrence rate, overall mortality, or CDI-related mortality. These observations suggest that resistance to rifaximin is not a marker for hypervirulent strains.
In our study, the most common ribotype was 001, which has one of the highest percentages of resistance to 3 or more classes of antibiotics [28] . We observed that 86.3% of ribotype 001 isolates were rifaximin resistant. In a previous study performed at our institution, we observed similar resistance rates for ribotype 001 [40] . In a few other studies assessing rifaximin resistance in C. difficile strains, resistant strains corresponded mostly to ribotypes 017 and 027 [18, 20, 41] . During the study, we recorded a very low number of episodes due to ribotype 027, and most were imported cases. This finding is consistent with data from that period in Spain [42, 43] .
Our study is limited by the fact that it is a retrospective, single-center study. However, to the best of our knowledge, it is the first to report such a high number of CDI cases in cirrhotic patients receiving rifaximin and the only one to perform a microbiological and molecular analysis of the C. difficile strains that caused the CDI episodes.
In conclusion, we found a considerable proportion of CDI cases occurring in cirrhotic patients receiving rifaximin. CDI was mostly due to selection of rifaximin-resistant C. difficile strains. Clinicians should be aware of the risk for CDI in cirrhotic patients, even in those receiving rifaximin. 
